Trial Profile
Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in Early Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms POP
- 25 Mar 2019 Results presented in the Cyclacel Pharmaceuticals Media Release
- 26 Feb 2019 Results published in the Journal of Clinical Oncology
- 11 Jun 2018 Primary endpoint (Anti proliferative response) has been met.